Newcelx LTD. (NCEL) — SEC Filings

Overview

Newcelx LTD. (NCEL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 1, 2026: NewcelX Ltd. filed a Form 6-K on April 1, 2026, reporting a Securities Purchase Agreement dated April 1, 2026. The filing includes exhibits detailing the form of the Securities Purchase Agreement, a Common Warrant, and a Pre-Funded Warrant, along with a press release from the same date. The company

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bullish, 42 neutral. The dominant filing sentiment for Newcelx LTD. is neutral.

Filing Type Overview

Newcelx LTD. (NCEL) has filed 49 6-K, 1 20-F with the SEC between Dec 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 6-K Filing — 6-K · Apr 20, 2026
• NewcelX Ltd. Files 6-K with Purchase Agreements and Warrants — 6-K · Apr 1, 2026 Risk: medium
  NewcelX Ltd. filed a Form 6-K on April 1, 2026, reporting a Securities Purchase Agreement dated April 1, 2026. The filing includes exhibits detailing the form o
• 6-K Filing — 6-K · Dec 11, 2025
• 6-K Filing — 6-K · Nov 20, 2025
• NewcelX Ltd. Adds Top Neurologist to Scientific Advisory Board — 6-K · Nov 17, 2025 Risk: low
  On November 17, 2025, NewcelX Ltd. announced the appointment of Dr. Jeremy Shefner, Chief Medical Officer at the Barrow Neurological Institute, to its Scientifi
• 6-K Filing — 6-K · Nov 7, 2025
• NewcelX Ltd. CEO Issues Letter to Shareholders — 6-K · Nov 4, 2025 Risk: low
  On November 4, 2025, NewcelX Ltd. (formerly NLS Pharmaceutics Ltd.) issued a press release containing a letter from its CEO to shareholders. The company, incorp
• 6-K Filing — 6-K · Nov 3, 2025
• NLS Pharma Expands CNS Pipeline with Aexon Labs' AEX-6xx Series — 6-K · Oct 30, 2025 Risk: medium
  On October 30, 2025, NLS Pharmaceutics Ltd. announced an expansion of its Central Nervous System (CNS) pipeline through the acquisition of the AEX-6xx series of
• NLS Pharmaceutics Merges Subsidiary with Kadimastem — 6-K · Oct 29, 2025 Risk: medium
  On November 4, 2024, NLS Pharmaceutics Ltd. announced a merger agreement where its subsidiary, NLS Pharmaceutics (Israel) Ltd., will merge with Kadimastem Ltd.
• NLS Pharmaceutics & Kadimastem Merger Conditions Met — 6-K · Oct 28, 2025 Risk: medium
  On October 28, 2025, NLS Pharmaceutics Ltd. announced the completion of material conditions precedent for its merger with Kadimastem. This announcement also con
• NLS Pharmaceutics Partners for Gene-Edited Cell Therapies — 6-K · Oct 27, 2025 Risk: medium
  On October 27, 2025, NLS Pharmaceutics Ltd. announced a strategic collaboration between its subsidiary TargetGene and Kadimastem. This partnership aims to advan
• NLS Pharmaceutics & Kadimastem Merger Gets Nasdaq Nod — 6-K · Oct 23, 2025 Risk: medium
  NLS Pharmaceutics Ltd. announced on October 23, 2025, that they received Nasdaq approval for their merger with Kadimastem. The merger is anticipated to close on
• NLS Pharmaceutics Ltd. Merges with Kadimastem Ltd. — 6-K · Oct 10, 2025 Risk: medium
  NLS Pharmaceutics Ltd. announced on October 10, 2025, that its wholly owned subsidiary, NLS Pharmaceutics (Israel) Ltd., entered into a Merger Agreement with Ka
• NLS Pharmaceutics Files Interim Financials — 6-K · Oct 6, 2025 Risk: low
  NLS Pharmaceutics Ltd. filed an Unaudited Interim Condensed Financial Statement on October 6, 2025, for the period ending June 30, 2025. This report includes fi
• NLS Pharmaceutics Shareholders Approve Merger with Kadimastem — 6-K · Sep 30, 2025 Risk: medium
  On September 30, 2025, NLS Pharmaceutics Ltd. announced that its shareholders approved the merger with Kadimastem and related proposals at an Extraordinary Gene
• NLS Pharmaceutics Auditor Resigns Amidst Business Acquisition — 6-K · Sep 19, 2025 Risk: medium
  NLS Pharmaceutics Ltd. was notified by its auditor, Marcum LLP, on September 17, 2025, that Marcum will resign immediately. This resignation is a result of CBIZ
• NLS Pharmaceutics Merger Registration Statement Effective — 6-K · Sep 10, 2025 Risk: medium
  On September 10, 2025, NLS Pharmaceutics Ltd. announced that the SEC registration statement related to its proposed merger with Kadimastem has become effective.
• NLS Pharmaceutics Secures Hong Kong Patent for Diabetes Tech — 6-K · Sep 4, 2025 Risk: medium
  On September 4, 2025, NLS Pharmaceutics Ltd. announced a patent granted in Hong Kong for cell-selection and enrichment technology related to its IsletRx product
• NLS Pharmaceutics Amends Merger Agreement for Seventh Time — 6-K · Aug 29, 2025 Risk: medium
  On August 29, 2025, NLS Pharmaceutics Ltd. entered into the Seventh Amendment to its Merger Agreement, originally dated November 4, 2024. This marks the seventh
• NLS Pharmaceutics Reschedules Shareholder Meeting for Kadimastem Deal — 6-K · Aug 25, 2025 Risk: medium
  NLS Pharmaceutics Ltd. announced on August 21, 2025, that it has rescheduled its Extraordinary Shareholders' Meeting, originally set for August 25, 2025. The me
• NLS Pharmaceutics Exchanges Warrants with Alpha Capital — 6-K · Aug 6, 2025 Risk: medium
  On August 5, 2025, NLS Pharmaceutics Ltd. entered into a warrant exchange agreement with Alpha Capital Anstalt. This agreement involves the exchange of a common
• NLS Pharmaceutics Amends Merger Agreement for Sixth Time — 6-K · Jul 18, 2025 Risk: medium
  On July 18, 2025, NLS Pharmaceutics Ltd. entered into a sixth amendment to its Merger Agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. This am
• NLS Pharma diabetes therapy gets BIRD Foundation milestone payment — 6-K · Jul 17, 2025 Risk: medium
  On June 17, 2025, NLS Pharmaceutics Ltd. announced that the BIRD Foundation approved an additional milestone payment to Kadimastem and iTolerance for the co-dev
• NLS Pharmaceutics Amends Merger Agreement Again — 6-K · Jul 1, 2025 Risk: medium
  On July 1, 2025, NLS Pharmaceutics Ltd. entered into the Fifth Amendment to its Merger Agreement, originally dated November 4, 2024. This amendment modifies the
• NLS Pharmaceutics Amends Private Placement Agreement — 6-K · Jun 30, 2025 Risk: low
  On June 26, 2025, NLS Pharmaceutics Ltd. amended its Securities Purchase Agreement from March 27, 2025, related to a private placement. The initial closing unde
• NLS Pharmaceutics CEO Letter to Shareholders Filed — 6-K · Jun 16, 2025 Risk: low
  On June 16, 2025, NLS Pharmaceutics Ltd. issued a press release containing a letter from its CEO to shareholders. The press release is furnished as Exhibit 99.1
• NLS Pharmaceutics Schedules June 30th Annual Shareholder Meeting — 6-K · Jun 10, 2025 Risk: low
  NLS Pharmaceutics Ltd. filed a Form 6-K on June 10, 2025, announcing its Annual General Shareholders' Meeting scheduled for June 30, 2025. Shareholders of recor
• NLS Pharmaceutics Amends Merger Agreement for Fourth Time — 6-K · Jun 6, 2025 Risk: medium
  On June 5, 2025, NLS Pharmaceutics Ltd. entered into a fourth amendment to its Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel)
• NLS Pharmaceutics Files 2024 Annual Report — 20-F · May 16, 2025 Risk: medium
  NLS Pharmaceutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Switzerland, is involved i
• NLS Pharmaceutics Amends Merger Agreement with Kadimastem — 6-K · May 5, 2025 Risk: medium
  On May 5, 2025, NLS Pharmaceutics Ltd. entered into a third amendment to its Merger Agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. This amen
• NLS Pharmaceutics Director Resigns — 6-K · Apr 24, 2025 Risk: low
  On April 18, 2025, Audrey Greenberg resigned from the Board of Directors of NLS Pharmaceutics Ltd. Her resignation was effective immediately and was not due to
• NLS Pharmaceutics: Mazindol Shows Promise Against Fentanyl Reward — 6-K · Apr 15, 2025 Risk: medium
  On April 15, 2025, NLS Pharmaceutics Ltd. announced positive results from its Study KO-943. The study demonstrated that Mazindol, a drug developed by the compan
• NLS Pharmaceutics Raises $3M in Private Placement — 6-K · Mar 31, 2025 Risk: medium
  On March 27, 2025, NLS Pharmaceutics Ltd. entered into a securities purchase agreement with three accredited investors for a private placement offering. The com
• NLS Pharmaceutics CEO Letter to Shareholders Filed — 6-K · Mar 10, 2025 Risk: low
  On March 10, 2025, NLS Pharmaceutics Ltd. issued a press release containing a letter from its CEO to shareholders. The filing itself is a Form 6-K, which is a r
• NLS Pharmaceutics: AEX-2 Preclinical Data Shows Promise — 6-K · Feb 27, 2025 Risk: medium
  On February 27, 2025, NLS Pharmaceutics Ltd. announced new preclinical data for its AEX-2 compound. This data suggests an expanded therapeutic potential for the
• NLS Pharmaceutics Subs Complete FDA Pre-IND Meeting for Diabetes Drug — 6-K · Feb 25, 2025 Risk: medium
  On February 25, 2025, NLS Pharmaceutics Ltd. announced that its subsidiaries Kadimastem and iTolerance successfully completed a Pre-IND meeting with the U.S. Fo
• NLS Pharma & Kadimastem Target Diabetes Beyond GLP-1 — 6-K · Feb 10, 2025 Risk: medium
  On February 10, 2025, NLS Pharmaceutics Ltd. announced a collaboration with Kadimastem to develop a multi-target approach for diabetes treatment, moving beyond
• NLS Pharmaceutics and Kadimastem Merger Approved — 6-K · Jan 31, 2025 Risk: medium
  On January 31, 2025, NLS Pharmaceutics Ltd. announced that Kadimastem shareholders approved the merger with NLS Pharmaceutics. This filing incorporates the pres
• NLS Pharmaceutics Submits Abstracts to ASCP Meeting — 6-K · Jan 30, 2025 Risk: low
  On January 30, 2025, NLS Pharmaceutics Ltd. announced the submission of three research abstracts to the 2025 ASCP Annual Meeting. This filing incorporates the p
• NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence — 6-K · Jan 28, 2025 Risk: medium
  On January 28, 2025, NLS Pharmaceutics Ltd. announced the initiation of a preclinical program for its drug Mazindol ER, aimed at treating fentanyl dependence. T
• NLS Pharmaceutics Merger Vote Scheduled — 6-K · Jan 16, 2025 Risk: medium
  On January 16, 2025, NLS Pharmaceutics Ltd. announced that Kadimastem has called for a Special General Meeting of Shareholders to approve a merger with NLS. Thi
• NLS Pharmaceutics Shareholders Approve All Agenda Items — 6-K · Jan 14, 2025 Risk: low
  On January 14, 2025, NLS Pharmaceutics Ltd. held an extraordinary shareholders' meeting where all proposed agenda items were approved. This report is incorporat
• NLS Pharmaceutics Closes $500K Fundraising at Premium — 6-K · Jan 8, 2025 Risk: medium
  NLS Pharmaceutics Ltd. announced on January 8, 2025, the initial closing of a $500,000 fundraising, part of a previously announced $1 million total. This fundra
• NLS Pharmaceutics Shareholders Approve Most Proposals — 6-K · Jan 7, 2025 Risk: low
  On January 7, 2025, NLS Pharmaceutics Ltd. held an extraordinary shareholders' meeting where all proposed agenda items were approved, except for Proposal 6, whi
• NLS Pharma & Kadimastem File F-4 for Merger — 6-K · Dec 30, 2024 Risk: medium
  On December 30, 2024, NLS Pharmaceutics Ltd. announced the filing of an F-4 registration statement with the SEC. This filing is in anticipation of a proposed me
• NLS Pharmaceutics Schedules Shareholder Meeting for Jan 14 — 6-K · Dec 23, 2024 Risk: low
  NLS Pharmaceutics Ltd. has scheduled an Extraordinary Shareholders' Meeting for January 14, 2025. Shareholders of record as of December 23, 2024, will be eligib
• NLS Pharma & Kadimastem Seek FDA Meeting for Diabetes Treatment — 6-K · Dec 19, 2024 Risk: medium
  On December 19, 2024, NLS Pharmaceutics Ltd. announced that its partner Kadimastem and its subsidiary iTolerance, Inc. have submitted a request to the FDA for a
• NLS Pharmaceutics Schedules Shareholder Meeting for Jan 7 — 6-K · Dec 17, 2024 Risk: low
  NLS Pharmaceutics Ltd. announced an Extraordinary Shareholders' Meeting scheduled for January 7, 2025. Shareholders of record as of December 16, 2024, are eligi
• NLS Pharmaceutics CEO Letter to Shareholders Filed — 6-K · Dec 11, 2024 Risk: low
  On December 11, 2024, NLS Pharmaceutics Ltd. filed a Form 6-K to report the issuance of a press release. This press release, titled "NLS Pharmaceutics CEO Issue

Risk Profile

Risk Assessment: Of NCEL's 45 recent filings, 0 were flagged as high-risk, 31 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Jeremy Shefner, MD, PhD
• Alexander Zwyer
• Audrey Greenberg

Top Tags

merger (12) · shareholder-meeting (7) · acquisition (6) · amendment (6) · corporate-governance (6) · pharmaceuticals (5) · press-release (5) · diabetes (5) · drug-development (5) · shareholder-communication (4)

Key Numbers

• Filing Type: 6-K — Report of Foreign Private Issuer
• Common Shares: 207,913 — Number of shares subject to the exchanged warrant
• Preferred Shares Issued: 1,212,122 — Issued as part of the private placement under the amended agreement.
• Par Value per Share: CHF 0.03 — The nominal value of each preferred share issued.
• Private Placement Proceeds: $3 million — Capital raised to fund operations and development.
• Initial Fundraising Closing: $500,000 — Represents the first tranche of capital raised.
• Total Announced Fundraising: $1 Million — The full target amount for the current fundraising effort.
• Share Price: $3.10 — The price per share at which the fundraising was conducted.
• Premium to Market Price: 48% — Indicates investor willingness to pay above current market value.

Related Companies

NLS · KDST

Frequently Asked Questions